Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | GALR3 | O60755 | 1/20 | 0.35 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.35 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.32 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.32 |
| ▸ | LCK | P06239 | 1/20 | 0.30 |
| ▸ | RET | P07949 | 1/20 | 0.30 |
| ▸ | SRC | P12931 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24170628 | 0.90 | ADK (0.42) | ADKNPC1GALR3S1PR4ALDH1A1 | |
| SCHEMBL18483552 | 0.87 | ADK (0.42) | ADKNPC1GALR3S1PR4ALDH1A1 | |
| SCHEMBL31228221 | 0.87 | ADK (0.42) | ADKNPC1GALR3S1PR4ALDH1A1 | |
| SCHEMBL19101933 | 0.86 | ADK (0.35) | ADKNPC1GALR3S1PR4ALDH1A1 | |
| SCHEMBL19101832 | 0.82 | ADK (0.44) | ADKPAX8DNMT1 | |
| SCHEMBL18503333 | 0.82 | ADK (0.39) | ADKNPC1GALR3S1PR4ALDH1A1 | |
| SCHEMBL31228217 | 0.82 | ADK (0.39) | ADKNPC1GALR3S1PR4ALDH1A1 | |
| SCHEMBL18483827 | 0.79 | ALDH1A1 (0.57) | ADKNPC1GALR3S1PR4ALDH1A1 | |
| SCHEMBL18483497 | 0.79 | ALDH1A1 (0.57) | ADKNPC1GALR3S1PR4ALDH1A1 | |
| SCHEMBL18503328 | 0.79 | ALDH1A1 (0.57) | ADKNPC1GALR3S1PR4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220002335-A1 | PYRROLOPYRIMIDINE NUCLEOSIDES AND ANALOGS THEREOF | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE | 2022-01-06 | — | — | US | disclosed |
| US-9701706-B2 | Pyrrolopyrimidine nucleosides and analogs thereof | CHIMERIX, INC. (US) | 2017-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220002335-A1 | PYRROLOPYRIMIDINE NUCLEOSIDES AND ANALOGS THEREOF | TYMP, PNP, DPYD | ADK 566/4885NPC1 238/4885GALR3 4655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.